The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.

1,5 Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug application for nerandomilast for the treatment of IPF to the ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...

The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...

MMH, a Boehringer Ingelheim initiative, began in 2010 as a partnership with the social entrepreneur network Ashoka. Since then, it has evolved into a many-faceted program, which is continuously ...